Multicenter, randomized, double‐blind phase 2 trial of <scp>FOLFIRI</scp> with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer - Concepedia

Concepedia

Publication | Open Access

Multicenter, randomized, double‐blind phase 2 trial of <scp>FOLFIRI</scp> with regorafenib or placebo as second‐line therapy for metastatic colorectal cancer

DOI Full Paper Access

36

Citations

14

References

2018

Year

Hanna K. Sanoff, Richard M. Goldberg, Anastasia Ivanova, Séamus O’Reilly, Samer S. Kasbari, Richard D. Kim, Ray McDermott, Dominic T. Moore, William C. Zamboni, William Grogan,

Abstract

The addition of regorafenib to FOLFIRI as second-line therapy for metastatic colorectal cancer only modestly prolonged PFS over FOLFIRI alone. Cancer 2018. © 2018 American Cancer Society.

References

	Year	Citations

Page 1